InterCure (NASDAQ:INCR) Shares Down 2.4% – Time to Sell?

Shares of InterCure Ltd. (NASDAQ:INCR) dropped 2.4% during mid-day trading on Monday. The company traded as low as $4.46 and last traded at $4.46. Approximately 1,822 shares traded hands during trading, a decline of 64% from the average session volume of 5,079 shares. The stock had previously closed at $4.57.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of InterCure in a research note on Tuesday, October 6th. One equities research analyst has rated the stock with a Sell rating. According to MarketBeat.com, the stock presently has an average rating of “Sell”.

InterCure Stock Performance

The firm’s fifty day moving average price is $5.15 and its two-hundred day moving average price is $4.78.

InterCure Company Profile

InterCure Ltd., operating under the Canndoc brand, is a vertically integrated cannabis company focused primarily on the medical cannabis market. The company’s activities include cannabis cultivation, processing, manufacturing, distribution and the sale of cannabis products through authorized channels.

InterCure offers medical cannabis flower and other cannabis-based products under brands including Canndoc and related consumer and medical product lines. Its business has historically been centered in Israel, where it operates within the country’s regulated medical cannabis framework and serves patients through licensed distribution channels and pharmacies.

Founded in 2013, InterCure has also pursued international expansion through partnerships, exports and market-development initiatives in selected overseas jurisdictions, including parts of Europe.